← Eichor
Study identifier: NCT06363370 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections

Condition: Respiratory Syncytial Virus Infections  ·  Sponsor: Kexing Biopharm Co., Ltd.

PhasePhase 3
Planned participants322
Who can joinAll sexes, 2 Months to 2 Years
Healthy volunteersNo

About this study

To evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection.

This description comes directly from the study's public registry record.

Talk to the study team

Jiajun Xu  ·  86-18851892277  ·  xujiajun@kexing.com

Ling Cao  ·  13910610319

Always discuss trial participation with your own doctor first.

Locations (1)

Children's Hospital, Capital Institute of PediatricsBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06363370